CD4+ T cell responses to self- and mutated p53 determinants during tumorigenesis in mice

被引:22
作者
Fedoseyeva, EV
Boisgérault, F
Anosova, NG
Wollish, WS
Arlotta, P
Jensen, PE
Ono, SJ
Benichou, G
机构
[1] Harvard Univ, Sch Med, Cellular & Mol Immunol Lab, Schepens Eye Res Inst, Boston, MA 02114 USA
[2] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA
[3] Univ Calif San Francisco, Dept Surg, Immunogenet & Transplantat Lab, San Francisco, CA 94143 USA
关键词
D O I
10.4049/jimmunol.164.11.5641
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We analyzed CD4(+) T helper responses to wild-type (wt) and mutated (mut) p53 protein in normal and tumor-bearing mice. In normal mice, we observed that although some self-p53 determinants induced negative selection of p53-reactive CD4(+) T cells, other p53 determinants (cryptic) were immunogenic, Next, BALB/c mice were inoculated with J774 syngeneic tumor cell line expressing mut p53, BALB/c tumor-bearing mice mounted potent CD4(+) T cell responses to two formerly cryptic peptides on self-p53. This response was characterized by massive production of IL-5, a Th2-type lymphokine. Interestingly, we found that T cell response was induced by different p53 peptides depending upon the stage of cancer. Mut p53 gene was shown to contain a single mutation resulting in the substitution of a tyrosine by a histidine at position 231 of the protein. Two peptides corresponding to wt and mutated sequences of this region were synthesized. Both peptides bound to the MHC class II-presenting molecule (E-d) With Similar affinities. However, only mut p53.225-239 induced T cell responses in normal BALB/c mice, a result strongly suggesting that high-affinity wt p53.225-239 autoreactive T cells had been eliminated in these mice. Surprisingly, CD4(+) T cell responses to both mut and wt p53.225-239 peptides were recorded in J774 tumor-bearing mice, a phenomenon attributed to the recruitment of low-avidity p53.225-239 self-reactive T cells.
引用
收藏
页码:5641 / 5651
页数:11
相关论文
共 51 条
[1]  
Armstrong TD, 1998, J IMMUNOL, V160, P661
[2]   Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity [J].
Armstrong, TD ;
Clements, VK ;
Martin, BK ;
Ting, JPY ;
OstrandRosenberg, S .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (13) :6886-6891
[3]   IMMUNOGENICITY AND TOLEROGENICITY OF SELF-MAJOR HISTOCOMPATIBILITY COMPLEX PEPTIDES [J].
BENICHOU, G ;
TAKIZAWA, PA ;
HO, PT ;
KILLION, CC ;
OLSON, CA ;
MCMILLAN, M ;
SERCARZ, EE .
JOURNAL OF EXPERIMENTAL MEDICINE, 1990, 172 (05) :1341-1346
[4]   Tumor antigens [J].
Boon, T ;
Old, LJ .
CURRENT OPINION IN IMMUNOLOGY, 1997, 9 (05) :681-683
[5]   IN-VIVO GENE-THERAPY OF HUMAN LUNG-CANCER USING WILD-TYPE P53 DELIVERED BY RETROVIRUS [J].
CARBONE, DP ;
MINNA, JD .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (19) :1437-1438
[6]  
Ciernik IF, 1996, J IMMUNOL, V156, P2369
[7]   p53-based immunotherapy of cancer [J].
DeLeo, AB .
CRITICAL REVIEWS IN IMMUNOLOGY, 1998, 18 (1-2) :29-35
[8]   THE MDM-2 ONCOGENE CAN OVERCOME WILD-TYPE P53 SUPPRESSION OF TRANSFORMED-CELL GROWTH [J].
FINLAY, CA .
MOLECULAR AND CELLULAR BIOLOGY, 1993, 13 (01) :301-306
[9]  
Fujita H, 1998, EUR J IMMUNOL, V28, P305, DOI 10.1002/(SICI)1521-4141(199801)28:01<305::AID-IMMU305>3.0.CO
[10]  
2-3